Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
A Multicenter, Randomized, Double-blind, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate to Severe Plaque Psoriasis
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Caihong Huang
- Telefonnummer: 020-62726806
- E-mail: caihong.huang.ch57@hengrui.com
Studiesteder
-
-
Guangzhou
-
Guangzhou, Guangzhou, Kina, 510091
- Rekruttering
- Dermatology Hospital Hospital of Southern Medical University
-
Ledende efterforsker:
- Bin Yang
-
Ledende efterforsker:
- Xiaohua Wang
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- During the screening process, the body mass index (BMI = weight (kg) / height^2 (m^2)) was ≥ 18 kg/m^2;
- History of plaque psoriasis for more than 6 months before randomization;
- The PASI score, sPGA score, and BSA at the screening and baseline required certain requirements;
- Participants suitable for phototherapy or systemic psoriasis treatment for moderate to severe plaque psoriasis;
- Participants voluntarily signed the informed consent before any procedures related to the study, could communicate smoothly with the researchers, understood and were willing to strictly follow the requirements of this clinical study protocol to complete the study;
- Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until 72 weeks after the last medication, had no plans for pregnancy, sperm donation, or egg donation, and voluntarily took effective contraceptive measures. The pregnancy test results of female participants during the screening period and before random administration should be negative, and must be non-lactating.
Exclusion Criteria:
-
The following conditions or diseases must be absent:
- The diagnosed psoriasis at the screening or baseline stage is not chronic plaque-type psoriasis;
- Has drug-induced psoriasis;
- Has other skin problems that the investigator considers would interfere with the assessment of psoriasis;
- Has concurrent other active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, multiple sclerosis or other central demyelinating diseases, primary Sjögren's syndrome, etc.;
Using the following drugs or participating in clinical studies:
- During the pre-baseline period, other biological agents had been used but did not meet the washout requirements.
- Has used drugs targeting the same target before the screening;
- Has received systemic psoriasis treatment drugs within the specified period before the baseline;
- Has received topical psoriasis treatment drugs within the specified period before the baseline;
- Has received phototherapy within the specified period before the baseline;
- Has participated in any clinical study of drugs or medical devices within 3 months before the baseline or within the drug's half-life period;
Important conditions or underlying diseases that affect safety:
- The participant has a history of lymphocytic proliferative diseases;
- The participant has had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening;
- Has a history of moderate to severe congestive heart failure (NYHA cardiac function classification ≥ III) within 3 months before the screening, has experienced cardiovascular or cerebrovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study;
- Has had opportunistic infections or immunodeficiency diseases within the previous 6 months before the screening;
- Has had active infections requiring oral anti-infection treatment within 2 weeks before the baseline, or has had severe infections or systemic infections within 4 weeks before the baseline, requires intravenous anti-infection treatment or is hospitalized due to infection, or other chronic, recurrent, active infections that the investigator deems unsuitable for participation in this study;
- Has active tuberculosis (TB) or latent TB infection;
- Has human immunodeficiency virus antibody (HIV) positive at screening, or hepatitis C virus (HCV) antibody positive and further HCV-RNA quantitative positive; or hepatitis B surface antigen (HBsAg) positive; or HBsAg negative but HBcAb positive, and further HBV-DNA test positive; or Treponema pallidum specific antibody positive.
- Has severe, progressive, uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane diseases, and other conditions that the investigator considers that the patient is not suitable to join this trial;
- Laboratory tests and/or 12-lead electrocardiogram (ECG) results are abnormal at screening:
General situation:
- Pregnant or lactating women;
- Allergic to any component of the test drug;
- Had a history of alcohol abuse or illegal drug use within the previous year before the screening;
- Had blood donation of approximately 500 mL within the previous 8 weeks before randomization or had a blood donation plan during the study;
- Had major surgery within the previous 8 weeks before screening, or had related surgery plans during the study;
- The investigator judges that there are other situations that affect the safety and efficacy evaluation of the test drug.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment group A: SHR-1139 injection/placebo
|
placebo
The SHR-1139 injection
|
|
Eksperimentel: Treatment group B: SHR-1139 injection/placebo
|
placebo
The SHR-1139 injection
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The proportion of participants who achieved a 100% improvement in the Psoriasis Area and Severity Index (PASI) score compared to the baseline by the 12th week (PASI 100).
Tidsramme: 12th week
|
12th week
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The proportion of participants who achieved a minimum improvement of at least 75% in PASI compared to the baseline (PASI 75) in the 12th week;
Tidsramme: 12th week
|
12th week
|
|
The proportion of participants who achieved a minimum improvement of at least 90% in PASI compared to the baseline (PASI 90) in the 12th week
Tidsramme: 12th week
|
12th week
|
|
The proportion of participants who achieved a sPGA response of 0 or 1 (sPGA 0/1) as assessed by the static physician in the 12th week
Tidsramme: 12th week
|
12th week
|
|
The proportion of participants who achieved a sPGA response of 0 (sPGA 0) in the 12th week
Tidsramme: 12th week
|
12th week
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SHR-1139-207
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .